Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07281495 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Taldefgrobep Alfa in Adults With Overweight and Obesity

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 20, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 20 of 20 sites
    v12
  2. Study sites: 19 to 20v11
  3. Study sites: 17 to 19v10
  4. Study sites: 16 to 17v9
  5. Study sites: 15 to 16v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 13 to 15v7
  2. Study sites: 10 to 13v6
  3. Study sites: 9 to 10v5
  4. Study sites: 7 to 9v4
  5. Study sites: 6 to 7v3
  6. Study sites: 4 to 6v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Trial Details
NCT Number NCT07281495
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions
(from sponsor)		 Obesity, Overweight
Related terms Obesity, Overweight
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov